



## OPEN ACCESS

## APPROVED BY

Michael Heinrich,  
University College London,  
United Kingdom

## \*CORRESPONDENCE

Frontiers Editorial Office,  
editorial.office@frontiersin.org

## SPECIALTY SECTION

This article was submitted to  
Ethnopharmacology,  
a section of the journal  
Frontiers in Pharmacology

RECEIVED 23 September 2022

ACCEPTED 23 September 2022

PUBLISHED 28 September 2022

## CITATION

Frontiers Editorial Office (2022),  
Retraction: Five active components  
compatibility of astragali radix and  
angelicae sinensis radix protect  
hematopoietic function against  
cyclophosphamide-induced injury in  
mice and t-BHP-induced injury  
in HSCs.  
*Front. Pharmacol.* 13:1051973.  
doi: 10.3389/fphar.2022.1051973

## COPYRIGHT

© 2022 Frontiers Editorial Office. This is  
an open-access article distributed  
under the terms of the [Creative  
Commons Attribution License \(CC BY\)](#).  
The use, distribution or reproduction in  
other forums is permitted, provided the  
original author(s) and the copyright  
owner(s) are credited and that the  
original publication in this journal is  
cited, in accordance with accepted  
academic practice. No use, distribution  
or reproduction is permitted which does  
not comply with these terms.

# Retraction: Five active components compatibility of astragali radix and angelicae sinensis radix protect hematopoietic function against cyclophosphamide-induced injury in mice and t-BHP-induced injury in HSCs

Frontiers Editorial Office\*

## A Retraction of the Original Research Article

[Five active components compatibility of astragali radix and angelicae sinensis radix protect hematopoietic function against cyclophosphamide-induced injury in mice and t-BHP-induced injury in HSCs](#)

by Zhang, W., Zhu, J.-h., Xu, H., Huang, X.-P., Liu, X.-D., and Deng, C.-Q. (2019). *Front. Pharmacol.* 10:936. doi: 10.3389/fphar.2019.00936

The journal retracts the 22 August 2019, article cited above.

Following publication, concerns were raised regarding the substantial similarity of content with two of the authors' previous publications. An investigation was conducted in accordance with Frontiers' policies, whereby it was confirmed that the degree of reuse of the previously published content is inconsistent with our editorial requirements for originality. Following the Committee on Publication Ethics guidelines, this article, published most recently, is retracted. This retraction was approved by the Chief Editors of Frontiers in Pharmacology, and the Chief Executive Editor of Frontiers. The authors agree to this retraction.

The authors concur with the retraction and sincerely regret any inconvenience this may have caused to the reviewers, editors, and readers of Frontiers in Pharmacology.